Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction

Marie Matignon, Ruchuang Ding, Darshana M. Dadhania, Franco B. Mueller, Choli Hartono, Catherine Snopkowski, Carol Li, John R. Lee, Daniel Sjoberg, Surya V. Seshan, Vijay K. Sharma, Hua Yang, Bakr Nour, Andrew J. Vickers, Manikkam Suthanthiran, Thangamani Muthukumar

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Noninvasive tests to differentiate the basis for acute dysfunction of the kidney allograft are preferable to invasive allograft biopsies. We measured absolute levels of 26 prespecified mRNAs in urine samples collected from kidney graft recipients at the time of for-cause biopsy for acute allograft dysfunction and investigated whether differential diagnosis of acute graft dysfunction is feasible using urinary cell mRNA profiles. We profiled 52 urine samples from 52 patients with biopsy specimens indicating acute rejection (26 acute T cell-mediated rejection and 26 acute antibody-mediated rejection) and 32 urine samples from 32 patients with acute tubular injury without acute rejection. A stepwise quadratic discriminant analysis ofmRNA measures identified a linear combination of mRNAs for CD3ε, CD105, TLR4, CD14, complement factor B, and vimentin that distinguishes acute rejection from acute tubular injury; 10-fold cross-validation of the six-gene signature yielded an estimate of the area under the curve of 0.92 (95% confidence interval, 0.86 to 0.98). In a decision analysis, the six-gene signature yielded the highest net benefit across a range of reasonable threshold probabilities for biopsy. Next, among patients diagnosed with acute rejection, a similar statistical approach identified a linear combination of mRNAs for CD3ε, CD105, CD14, CD46, and 18S rRNA that distinguishes T cell-mediated rejection from antibody-mediated rejection, with a cross-validated estimate of the area under the curve of 0.81 (95% confidence interval, 0.68 to 0.93). Incorporation of these urinary cell mRNA signatures in clinical decisions may reduce the number of biopsies in patients with acute dysfunction of the kidney allograft.

Original languageEnglish
Pages (from-to)1586-1597
Number of pages12
JournalJournal of the American Society of Nephrology
Volume25
Issue number7
DOIs
Publication statusPublished - 1 Jul 2014

Fingerprint

Differential Diagnosis
Allografts
Transplants
Kidney
Biopsy
Messenger RNA
Urine
Area Under Curve
Confidence Intervals
T-Lymphocytes
Complement Factor B
Decision Support Techniques
Antibodies
Wounds and Injuries
Discriminant Analysis
Vimentin
Genes

ASJC Scopus subject areas

  • Nephrology

Cite this

Matignon, M., Ding, R., Dadhania, D. M., Mueller, F. B., Hartono, C., Snopkowski, C., ... Muthukumar, T. (2014). Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction. Journal of the American Society of Nephrology, 25(7), 1586-1597. https://doi.org/10.1681/ASN.2013080900

Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction. / Matignon, Marie; Ding, Ruchuang; Dadhania, Darshana M.; Mueller, Franco B.; Hartono, Choli; Snopkowski, Catherine; Li, Carol; Lee, John R.; Sjoberg, Daniel; Seshan, Surya V.; Sharma, Vijay K.; Yang, Hua; Nour, Bakr; Vickers, Andrew J.; Suthanthiran, Manikkam; Muthukumar, Thangamani.

In: Journal of the American Society of Nephrology, Vol. 25, No. 7, 01.07.2014, p. 1586-1597.

Research output: Contribution to journalArticle

Matignon, M, Ding, R, Dadhania, DM, Mueller, FB, Hartono, C, Snopkowski, C, Li, C, Lee, JR, Sjoberg, D, Seshan, SV, Sharma, VK, Yang, H, Nour, B, Vickers, AJ, Suthanthiran, M & Muthukumar, T 2014, 'Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction', Journal of the American Society of Nephrology, vol. 25, no. 7, pp. 1586-1597. https://doi.org/10.1681/ASN.2013080900
Matignon, Marie ; Ding, Ruchuang ; Dadhania, Darshana M. ; Mueller, Franco B. ; Hartono, Choli ; Snopkowski, Catherine ; Li, Carol ; Lee, John R. ; Sjoberg, Daniel ; Seshan, Surya V. ; Sharma, Vijay K. ; Yang, Hua ; Nour, Bakr ; Vickers, Andrew J. ; Suthanthiran, Manikkam ; Muthukumar, Thangamani. / Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction. In: Journal of the American Society of Nephrology. 2014 ; Vol. 25, No. 7. pp. 1586-1597.
@article{f87f41061acc42339c8ba7ae736b3dac,
title = "Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction",
abstract = "Noninvasive tests to differentiate the basis for acute dysfunction of the kidney allograft are preferable to invasive allograft biopsies. We measured absolute levels of 26 prespecified mRNAs in urine samples collected from kidney graft recipients at the time of for-cause biopsy for acute allograft dysfunction and investigated whether differential diagnosis of acute graft dysfunction is feasible using urinary cell mRNA profiles. We profiled 52 urine samples from 52 patients with biopsy specimens indicating acute rejection (26 acute T cell-mediated rejection and 26 acute antibody-mediated rejection) and 32 urine samples from 32 patients with acute tubular injury without acute rejection. A stepwise quadratic discriminant analysis ofmRNA measures identified a linear combination of mRNAs for CD3ε, CD105, TLR4, CD14, complement factor B, and vimentin that distinguishes acute rejection from acute tubular injury; 10-fold cross-validation of the six-gene signature yielded an estimate of the area under the curve of 0.92 (95{\%} confidence interval, 0.86 to 0.98). In a decision analysis, the six-gene signature yielded the highest net benefit across a range of reasonable threshold probabilities for biopsy. Next, among patients diagnosed with acute rejection, a similar statistical approach identified a linear combination of mRNAs for CD3ε, CD105, CD14, CD46, and 18S rRNA that distinguishes T cell-mediated rejection from antibody-mediated rejection, with a cross-validated estimate of the area under the curve of 0.81 (95{\%} confidence interval, 0.68 to 0.93). Incorporation of these urinary cell mRNA signatures in clinical decisions may reduce the number of biopsies in patients with acute dysfunction of the kidney allograft.",
author = "Marie Matignon and Ruchuang Ding and Dadhania, {Darshana M.} and Mueller, {Franco B.} and Choli Hartono and Catherine Snopkowski and Carol Li and Lee, {John R.} and Daniel Sjoberg and Seshan, {Surya V.} and Sharma, {Vijay K.} and Hua Yang and Bakr Nour and Vickers, {Andrew J.} and Manikkam Suthanthiran and Thangamani Muthukumar",
year = "2014",
month = "7",
day = "1",
doi = "10.1681/ASN.2013080900",
language = "English",
volume = "25",
pages = "1586--1597",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction

AU - Matignon, Marie

AU - Ding, Ruchuang

AU - Dadhania, Darshana M.

AU - Mueller, Franco B.

AU - Hartono, Choli

AU - Snopkowski, Catherine

AU - Li, Carol

AU - Lee, John R.

AU - Sjoberg, Daniel

AU - Seshan, Surya V.

AU - Sharma, Vijay K.

AU - Yang, Hua

AU - Nour, Bakr

AU - Vickers, Andrew J.

AU - Suthanthiran, Manikkam

AU - Muthukumar, Thangamani

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Noninvasive tests to differentiate the basis for acute dysfunction of the kidney allograft are preferable to invasive allograft biopsies. We measured absolute levels of 26 prespecified mRNAs in urine samples collected from kidney graft recipients at the time of for-cause biopsy for acute allograft dysfunction and investigated whether differential diagnosis of acute graft dysfunction is feasible using urinary cell mRNA profiles. We profiled 52 urine samples from 52 patients with biopsy specimens indicating acute rejection (26 acute T cell-mediated rejection and 26 acute antibody-mediated rejection) and 32 urine samples from 32 patients with acute tubular injury without acute rejection. A stepwise quadratic discriminant analysis ofmRNA measures identified a linear combination of mRNAs for CD3ε, CD105, TLR4, CD14, complement factor B, and vimentin that distinguishes acute rejection from acute tubular injury; 10-fold cross-validation of the six-gene signature yielded an estimate of the area under the curve of 0.92 (95% confidence interval, 0.86 to 0.98). In a decision analysis, the six-gene signature yielded the highest net benefit across a range of reasonable threshold probabilities for biopsy. Next, among patients diagnosed with acute rejection, a similar statistical approach identified a linear combination of mRNAs for CD3ε, CD105, CD14, CD46, and 18S rRNA that distinguishes T cell-mediated rejection from antibody-mediated rejection, with a cross-validated estimate of the area under the curve of 0.81 (95% confidence interval, 0.68 to 0.93). Incorporation of these urinary cell mRNA signatures in clinical decisions may reduce the number of biopsies in patients with acute dysfunction of the kidney allograft.

AB - Noninvasive tests to differentiate the basis for acute dysfunction of the kidney allograft are preferable to invasive allograft biopsies. We measured absolute levels of 26 prespecified mRNAs in urine samples collected from kidney graft recipients at the time of for-cause biopsy for acute allograft dysfunction and investigated whether differential diagnosis of acute graft dysfunction is feasible using urinary cell mRNA profiles. We profiled 52 urine samples from 52 patients with biopsy specimens indicating acute rejection (26 acute T cell-mediated rejection and 26 acute antibody-mediated rejection) and 32 urine samples from 32 patients with acute tubular injury without acute rejection. A stepwise quadratic discriminant analysis ofmRNA measures identified a linear combination of mRNAs for CD3ε, CD105, TLR4, CD14, complement factor B, and vimentin that distinguishes acute rejection from acute tubular injury; 10-fold cross-validation of the six-gene signature yielded an estimate of the area under the curve of 0.92 (95% confidence interval, 0.86 to 0.98). In a decision analysis, the six-gene signature yielded the highest net benefit across a range of reasonable threshold probabilities for biopsy. Next, among patients diagnosed with acute rejection, a similar statistical approach identified a linear combination of mRNAs for CD3ε, CD105, CD14, CD46, and 18S rRNA that distinguishes T cell-mediated rejection from antibody-mediated rejection, with a cross-validated estimate of the area under the curve of 0.81 (95% confidence interval, 0.68 to 0.93). Incorporation of these urinary cell mRNA signatures in clinical decisions may reduce the number of biopsies in patients with acute dysfunction of the kidney allograft.

UR - http://www.scopus.com/inward/record.url?scp=84905676008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905676008&partnerID=8YFLogxK

U2 - 10.1681/ASN.2013080900

DO - 10.1681/ASN.2013080900

M3 - Article

C2 - 24610929

AN - SCOPUS:84905676008

VL - 25

SP - 1586

EP - 1597

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 7

ER -